Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial exchanges : Nasdaq save search
Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection
Published: 2024-04-19 (Crawled : 22:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
infection antibiotics trials for
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
Published: 2024-04-19 (Crawled : 20:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
| Email alert
Add to watchlist
pharmaceuticals trial
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Published: 2024-04-19 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: -15.41%
H: 6.2%
C: 2.33%
ocu410 armada trial therapy
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.7013 -17.98% -21.92% 420K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | $17.65 -2.4% 4K
|
Health Technology
|
| O: -0.87%
H: 3.58%
C: -2.86%
nephropathy congress world nefecon trial therapeutics
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.89 1.03% 1.02% 250K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
BPTH | News 0 d | $4.17 -0.71% -0.96% 2.1M
|
Health Technology
|
| O: 72.84%
H: 41.77%
C: -22.37%
bp1002 leukemia trial
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: 0.0%
jeuveau publication for study
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: -2.42%
H: 0.0%
C: 0.0%
allonk first candidate lupus cell trial therapy
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Published: 2024-04-17 (Crawled : 12:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K
|
Health Technology
|
| O: 8.53%
H: 0.0%
C: -6.23%
da-1726 obesity first treatment pharmaceuticals for trial
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K
|
Manufacturing
|
| O: 0.25%
H: 0.0%
C: 0.0%
evx-01 first vaccine cancer trial
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
Published: 2024-04-17 (Crawled : 11:00) - globenewswire.com
CTSO | $0.8026 0.2% 0.2% 46K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
association presentation for meeting trial results
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Published: 2024-04-16 (Crawled : 00:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
tezspire copd
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
management company cell nurown trial therapeutics
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CLPT | $5.35 -0.74% -0.75% 130K
|
Health Technology
| Email alert
Add to watchlist
avb-101 first dementia for trial
New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 15:00) - hancockjaffe.com
NVNO | $4.65 -2.72% -2.8% 71K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
venovalve symposium topline medical trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.